2 weeks Ago By ABMN Staff
Gritstone bio, Inc. ( NASDAQ:GRTS – Free Report ) – Investment analysts at B. Riley lifted their FY2024 earnings per share (EPS) estimates for Gritstone bio in a research note issued on Wednesday, August 28th.
B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.
98) for the year, up from their prior forecast of ($0.99). B.
Riley has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Gritstone bio’s current full-year earnings is ($0.
99) per share. B. Riley also issued estimates for Gritstone bio’s Q4 2024 earnings at ($0.
15) EPS and FY2025 earnings at ($0.91) EPS. A number of other research firms also recently commented on GRTS.
JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Gritstone bio in a research report on Monday, August 5th. HC Wainwright restated a “buy” rating and set a $4.
00 target price on shares of Gritstone bio in a report on Thursday, August 15th. Gritstone bio Stock Down 2.1 % Shares of NASDAQ GRTS opened at $0.
45 on Friday. The stock has a 50 day moving average price of $0.59 and a 200 day moving average price of $1.
14. The firm has a market capitalization of $49.09 million, a price-to-earnings ratio of -0.
36 and a beta of 0.50. Gritstone bio has a 52-week low of $0.
45 and a 52-week high of $3.33. The company has a debt-to-equity ratio of 2.
89, a quick ratio of 2.00 and a current ratio of 2.00.
Gritstone bio ( NASDAQ:GRTS – Get Free Report ) last released its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.
28) by $0.12. The business had revenue of $0.
92 million for the quarter, compared to analyst estimates of $2.77 million. Gritstone bio had a negative return on equity of 232.
42% and a negative net margin of 926.13%. Institutional Trading of Gritstone bio A number of institutional investors have recently bought and sold shares of GRTS.
Artal Group S.A. acquired a new stake in shares of Gritstone bio during the first quarter worth $2,650,000.
Victory Capital Management Inc. raised its stake in Gritstone bio by 4,598.5% in the 2nd quarter.
Victory Capital Management Inc. now owns 553,150 shares of the company’s stock worth $342,000 after acquiring an additional 541,377 shares during the last quarter. Vanguard Group Inc.
grew its stake in Gritstone bio by 7.2% during the 1st quarter. Vanguard Group Inc.
now owns 4,733,791 shares of the company’s stock valued at $12,166,000 after purchasing an additional 317,499 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Gritstone bio in the 1st quarter worth approximately $636,000. Finally, Point72 Asia Singapore Pte.
Ltd. purchased a new position in Gritstone bio during the 2nd quarter worth approximately $96,000. 48.
46% of the stock is currently owned by institutional investors and hedge funds. Gritstone bio Company Profile ( Get Free Report ) Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.
Featured Articles Receive News & Ratings for Gritstone bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone bio and related companies with MarketBeat.com's FREE daily email newsletter ..
